Back to News
Market Impact: 0.6

Lonza Group H1 Results Up; Lifts FY25 CDMO Sales, Margins Outlook

NDAQ
Corporate EarningsCorporate Guidance & OutlookCompany FundamentalsHealthcare & Biotech
Lonza Group H1 Results Up; Lifts FY25 CDMO Sales, Margins Outlook

Lonza Group AG reported a robust first-half 2025, with profit climbing 29% to CHF 426 million and sales up 17% (19% CER) to CHF 3.58 billion, primarily driven by its CDMO business. Consequently, the company raised its fiscal 2025 guidance for the CDMO segment, now projecting 20-21% CER sales growth and a 30-31% CORE EBITDA margin, while maintaining its outlook for the CHI business. This significant upgrade underscores Lonza's strong operational momentum and improved financial prospects.

Analysis

Lonza Group AG reported a significant acceleration in financial performance for the first half of 2025, underscored by a 29% increase in net profit to 426 million Swiss francs and a 17% rise in sales to 3.58 billion Swiss francs (19% at constant exchange rates). This robust growth was primarily propelled by strong operational execution in its Contract Development and Manufacturing Organization (CDMO) business. The positive momentum led management to upgrade its full-year 2025 guidance for this key division, now forecasting CER sales growth of 20-21% and an improved CORE EBITDA margin of 30-31%. This upward revision, combined with the reaffirmation of a stable outlook for its CHI business—which anticipates low-to-mid single-digit sales growth and a CORE EBITDA margin in the mid-twenties—signals strong confidence in sustained profitability and top-line expansion for the remainder of the fiscal year.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

strongly positive

Sentiment Score

0.80

Ticker Sentiment

NDAQ0.00

Key Decisions for Investors

  • The strong earnings beat and upward guidance revision for the high-margin CDMO segment justify a bullish outlook and may warrant an increase in full-year earnings estimates.
  • Investors should monitor the company's second-half performance to ensure it sustains the guided 30-31% CORE EBITDA margin in the CDMO business, as this is now the central pillar of the investment case.
  • Given the differentiated growth outlooks, it is prudent to assess the relative contribution of the CDMO and CHI segments and watch for any acceleration in the CHI market recovery, which would represent further potential upside.